The best VC’s for developing Therapeutics in Europe?

The VC’s investing in Europe can be ranked by the number of times they have participated in a EUR >50M M&A of a company developing therapeutics. In Sunstone’s analysis of the 56 M&As that took place in the period 2010-2020, 243 named investors participated. Only 27 investors participated in 3 or more transactions; they are ranked in the figure below.

Sunstone is proud to have been part of a significant number of M&As and thus joining a group of peers that include some of Europe’s oldest and largest VC’s.

We get wiser every time we sell a company and moreover, we expand our network – and we believe that to be true for our colleagues as well.

Should you pay extra attention when the investors below ask you to consider an investment opportunity?

What do you think?
Let us know in our feed on LinkedIn:
Back to News & Insights overview

5 latest press releases

Teitur Trophics Raises EUR 28M in Series A Financing to advance the development and treatment for neurodegenerative diseases

Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and...
Read more

Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part...
Read more

Sunstone Life Science Ventures is looking for a Student Assistant

No longer accepting applications We are looking for a student to join our team for approximately 8 hours a week. As part of the team, you will play a pivotal role in the management of our deal flow, which lies in the order of 400-500 opportunities every year....
Read more

Sunstone announce new investment in immuno-oncology company STipe Therapeutics

Sunstone Life Science Ventures today announce it has invested in new portfolio company Stipe Therapeutics ApS (“STipe”), an immuno-oncology company dedicated to developing novel cancer therapeutics based on its first class drugs modulating the STING pathway.

Read more

Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia

Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia...
Read more

5 latest articles

Sunstone has supported and funded companies that have been the originator of 20 life-changing products

Since the inception in 2007, Sunstone Life Science Ventures (Sunstone) has co-created, supported and funded life science companies that have been the originator of 20 life-changing products approved for the treatment or diagnosis of patients with cardiovascular,...
Read more

Biotech startups in Scandinavia have 460 MEUR at hand – but burn is up – and runway the shortest in 3 years

As the market continues to fluctuate and geopolitical issues continue to impact the economy, it's important to take a closer look at the state of pre-commercial life science companies. At Sunstone, we assisted companies in our portfolio with listings and refinancing,...
Read more

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?  For the past 5 months we have had the pleasure of having Philip Brainin as intern at Sunstone Life Science Ventures. Apart from bringing valuable insights to our daily activities, he has...
Read more

Why do VC’s not cut losses in time?

Why do VC’s not cut losses in time?  A clinical trial is a very expensive experiment for testing a hypothesis, while hoping for a positive outcome. However, if well designed, a negative outcome could increase the potential for a positive outcome in a subsequent trial....
Read more

Are some diseases associated with a higher risk of venture capital losses?

Are some diseases associated with a higher risk of venture capital losses?  Before summer we posted a study correlating venture capital losses in drug development with the magnitude of funding of clinical trials. We have used two approaches to find losses: 1)...
Read more

Do compromises in clinical trials cause Venture Capital losses?

Do compromises in clinical trials cause Venture Capital losses? In 2020 and 2021 Sunstone looked in depth at drug development venture-backed successes to find usable attributes and learn from the past. We have now turned the analysis up-side down and looked at the...
Read more